[extropy-chat] MitoKor- deferral of public offering

[Robert J. Bradbury]

With regard to MitoKor.  They made a presentation at the AGE
meeting in June 2002.  The evidence they presented
suggested that estrogen (or its analogues) were effective
antioxidants/free radical sinks within the mitochondria.

This of course explains why in general women live longer
than men.  Of course from a therapy standpoint the question
becomes why should one pay $XXX for an estrogen related
drug vs. $YYY (<< $XXX) for estrogen itself.

The MitoKor executives were very up-front in their presentations
that even though the felt they had compounds that were more
effective than estrogen they felt the investment/drug approval
climate made it pointless to attempt to pursue them.

Robert